Key result
Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve both cardiovascular and renal outcomes when added to guideline-recommended treatment for type 2 diabetes.
Why the study?
Narrow treatment strategies focused strictly on glycemic control in type 2 diabetes mellitus did not significantly reduce cardiovascular events or diabetic kidney disease progression.
Answers are grounded in this paper and cite their sources.
SGLT2 inhibitors provide significant cardiovascular and renal protection in patients with type 2 diabetes beyond glycemic control.
Poorly controlled type 2 diabetes mellitus is associated with the development of cardiovascular and renal complications, resulting in significant morbidity and mortality. Intensive glycemic control has been a major focus for clinical trials and novel drug development. However, narrow treatment strategies developed strictly for glycemic control did not confer a large risk reduction in cardiovascular events. There were also only modest effects in reducing the progression of diabetic kidney disease. Recent cardiovascular safety trials and the dedicated renal protection trial CREDENCE (Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy) have shown that the sodium-glucose cotransporter-2 (SGLT2) inhibitors, a newer generation of antihyperglycemic agents, improve both cardiovascular and renal outcomes when added to guideline-recommended treatment. This review examines the current evidence on the mechanism underlying the cardiorenal effects of SGLT2 inhibitors and summarizes clinical trial evidence and safety data related to the use of SGLT2 inhibitors for cardiovascular and renal protection.
No takes yet. Share an insight, caveat, or question.
Cherney et al. (2019) conducted a review in Type 2 diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors was evaluated. Sodium-glucose cotransporter-2 (SGLT2) inhibitors improve both cardiovascular and renal outcomes when added to guideline-recommended treatment for type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: